Takeda Pharmaceutical Co Stock Net Income

TAK Stock  USD 14.19  0.20  1.39%   
Takeda Pharmaceutical Co fundamentals help investors to digest information that contributes to Takeda Pharmaceutical's financial success or failures. It also enables traders to predict the movement of Takeda Stock. The fundamental analysis module provides a way to measure Takeda Pharmaceutical's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Takeda Pharmaceutical stock.
At this time, Takeda Pharmaceutical's Net Income From Continuing Ops is quite stable compared to the past year. Net Income Applicable To Common Shares is expected to rise to about 382.8 B this year, although the value of Net Income will most likely fall to about 221.8 B.
  
This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

Takeda Net Income Analysis

Takeda Pharmaceutical's Net income is the profit of a company for the reporting period, which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most-watched numbers by money managers as well as individual investors.

Takeda Pharmaceutical Net Income

159.86 Billion

Net Income

 = 

(Rev + Gain)

-

(Exp + Loss)

More About Net Income | All Equity Analysis

Current Takeda Pharmaceutical Net Income

    
  317.04 B  
Most of Takeda Pharmaceutical's fundamental indicators, such as Net Income, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Takeda Pharmaceutical Co is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
Competition

Takeda Accumulated Other Comprehensive Income

Accumulated Other Comprehensive Income

1.82 Trillion

At this time, Takeda Pharmaceutical's Accumulated Other Comprehensive Income is quite stable compared to the past year.
Based on the recorded statements, Takeda Pharmaceutical Co reported net income of 317.04 B. This is much higher than that of the Pharmaceuticals sector and significantly higher than that of the Health Care industry. The net income for all United States stocks is significantly lower than that of the firm.

Takeda Net Income Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Takeda Pharmaceutical's direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Takeda Pharmaceutical could also be used in its relative valuation, which is a method of valuing Takeda Pharmaceutical by comparing valuation metrics of similar companies.
Takeda Pharmaceutical is currently under evaluation in net income category among related companies.

Takeda Pharmaceutical Institutional Holders

Institutional Holdings refers to the ownership stake in Takeda Pharmaceutical that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Takeda Pharmaceutical's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Takeda Pharmaceutical's value.
Shares
Northern Trust Corp2023-12-31
1.8 M
Blackrock Inc2023-12-31
1.8 M
Managed Asset Portfolios, Llc2023-12-31
1.8 M
Envestnet Asset Management Inc2023-12-31
1.6 M
Causeway Capital Management Llc2023-12-31
1.3 M
Van Eck Associates Corporation2023-12-31
1.3 M
Y.d. More Investments Ltd2023-12-31
1.3 M
Old Mission Capital Llc2023-12-31
M
Bank Of America Corp2023-12-31
834.3 K
Capital Research Global Investors2023-12-31
14.3 M
Goldman Sachs Group Inc2023-12-31
8.6 M

Takeda Fundamentals

About Takeda Pharmaceutical Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Takeda Pharmaceutical Co's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Takeda Pharmaceutical using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Takeda Pharmaceutical Co based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Last ReportedProjected for 2024
Net Income285.3 B221.8 B
Net Income From Continuing Ops364.6 B382.8 B
Net Income Applicable To Common Shares364.6 B382.8 B
Net Income Per E B T 0.76  0.54 

Currently Active Assets on Macroaxis

When determining whether Takeda Pharmaceutical is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if Takeda Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Takeda Pharmaceutical Co Stock. Highlighted below are key reports to facilitate an investment decision about Takeda Pharmaceutical Co Stock:
Check out Takeda Pharmaceutical Piotroski F Score and Takeda Pharmaceutical Altman Z Score analysis.
Note that the Takeda Pharmaceutical information on this page should be used as a complementary analysis to other Takeda Pharmaceutical's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Money Flow Index module to determine momentum by analyzing Money Flow Index and other technical indicators.

Complementary Tools for Takeda Stock analysis

When running Takeda Pharmaceutical's price analysis, check to measure Takeda Pharmaceutical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Takeda Pharmaceutical is operating at the current time. Most of Takeda Pharmaceutical's value examination focuses on studying past and present price action to predict the probability of Takeda Pharmaceutical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Takeda Pharmaceutical's price. Additionally, you may evaluate how the addition of Takeda Pharmaceutical to your portfolios can decrease your overall portfolio volatility.
Transaction History
View history of all your transactions and understand their impact on performance
Fundamental Analysis
View fundamental data based on most recent published financial statements
Commodity Channel
Use Commodity Channel Index to analyze current equity momentum
Piotroski F Score
Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals
Bonds Directory
Find actively traded corporate debentures issued by US companies
Analyst Advice
Analyst recommendations and target price estimates broken down by several categories
Balance Of Power
Check stock momentum by analyzing Balance Of Power indicator and other technical ratios
CEOs Directory
Screen CEOs from public companies around the world
AI Investment Finder
Use AI to screen and filter profitable investment opportunities
Is Takeda Pharmaceutical's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Takeda Pharmaceutical. If investors know Takeda will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Takeda Pharmaceutical listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
(0.12)
Dividend Share
184
Earnings Share
0.37
Revenue Per Share
1.3 K
Quarterly Revenue Growth
0.013
The market value of Takeda Pharmaceutical is measured differently than its book value, which is the value of Takeda that is recorded on the company's balance sheet. Investors also form their own opinion of Takeda Pharmaceutical's value that differs from its market value or its book value, called intrinsic value, which is Takeda Pharmaceutical's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Takeda Pharmaceutical's market value can be influenced by many factors that don't directly affect Takeda Pharmaceutical's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Takeda Pharmaceutical's value and its price as these two are different measures arrived at by different means. Investors typically determine if Takeda Pharmaceutical is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Takeda Pharmaceutical's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.